The genetic epidemiology of neurodegenerative disease
Open accessThe DOI matches its Crossref record; 103 of the 106 references it cites were found in a registry or an index.
Abstract
Gene defects play a major role in the pathogenesis of degenerative disorders of the nervous system.In fact, it has been the very knowledge gained from genetic studies that has allowed the elucidation of the molecular mechanisms underlying the etiology and pathogenesis of many neurodegenerative disorders.In this review, we discuss the current status of genetic epidemiology of the most common neurodegenerative diseases: Alzheimer disease, Parkinson disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, and prion diseases, with a particular focus on similarities and differences among these syndromes. The complexities of common diseasesFamilial aggregation had been recognized as a prominent characteristic of many neurodegenerative disorders decades before the underlying molecular genetic or biochemical properties were known.It was often the identification of specific, disease-segregating mutations in previously unknown genes that directed the attention to certain proteins and pathways that are now considered crucial in the pathogenesis of these diseases.These include mutations in the β-amyloid (Aβ) precursor protein, causing Alzheimer disease (AD); in α-synuclein, causing Parkinson disease (PD); or in microtubule-associated protein tau, causing frontotemporal dementia (FTD) with parkinsonism.Another feature observed in most common neurodegenerative diseases -as well as in other common disorders -is a dichotomy between familial (rare) and seemingly nonfamilial (common) forms.The latter are also frequently described as "sporadic" or "idiopathic," although there is a growing body of evidence suggesting that a large proportion of these cases are also significantly influenced by genetic factors.These risk genes are likely to be numerous, displaying intricate patterns of interaction with each other as well as with nongenetic variable, and -unlike classical Mendelian ("simplex") disorders -exhibit no simple or single mode of inheritance.Hence, the genetics of these diseases has been labeled "complex."A popular conception regarding the genetic makeup of complex diseases is the "common disease/common variant" (CD/CV) hypothesis (1).According to this theory common disorders are also governed by common DNA variants (such as single nucleotide polymorphisms.These variants significantly increase disease risk but are insufficient to actually cause a specific disorder.Current empirical and theoretical data support this hypothesis, although there remains great uncertainty as to the number of the underlying risk factors and their specific effect sizes.In this context, it is noteworthy that even recent genetic advances in the study of complex diseases such as AD or diabetes likely only represent the most obvi-ous, most extreme cases of the underlying risk spectrum (Figure 1; ref.2).In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e.APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.The identification of these genes early in the study of AD genetics was possible due to the combination of several favorable circumstances, such as the presence of multiple independent mutations in the same locus and the availability of extended, multigenerational pedigrees for DNA genotyping and sequencing (in the case of PSEN1) or a large attributable fraction to the overall genetic variance, resulting from relatively high allele frequency and pronounced effect size (in the case of APOE).However, identification of disease genes that make smaller overall contributions to the genetic spectrum (because of only few mutational events; e.g., PSEN2), or risk factors with smaller effect sizes (i.e.odds ratios [ORs] ranging between 2 and 3), will require much larger samples and possibly more sensitive and efficient analytic tools to enable consistent detection across study populations (2).Additional, and commonly cited, problems in finding complex disease genes beyond the most obvious are multiple testing, publication bias, and questionable replication (3-5).Multiple testing can be placed under the larger category of "avoidable false positive" findings, which are also caused by testing insufficiently sized samples, using inappropriate matching of cases versus controls, stratifying populations, and choosing inadequate analysis strategies, etc. Publication bias, on the other hand, which indicates the higher a priori likelihood of a positive finding being published as opposed to a negative one, may have been a possible source of serious bias in the early days.However, there is only relatively little empirical evidence that publication bias actually represents a common or significant source of error in current publications investigating the genetics of a number of disorders (e.g., refs.6-12).The sheer number of publications in the AD gene
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of Amyloid-β (Aβ) peptide initiates a cascade of events that ultimately result in Alzheimer’s disease (AD) [1–4].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 4×
“The most frequently involved gene in recessive parkinsonism is parkin (PRKN) on chromosome 6q25 (33, 41), which causes nearly half of all early-onset PD cases.”
BackgroundInfluentialGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 5×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluentialα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“AD APP (15) Aβ precursor protein 21q21 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) and aggregation AD APOE (21, 22) Apolipoprotein E 19q13 Risk factor Unknown (Aβ aggregation? lipid metabolism?) AD PSEN1 (16) Presenilin 1 14q24 Dominant Altered Aβ production (Aβ42/Aβ40 ratio ↑) AD PSEN2 (17, 18) Presenilin 2 1q…”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 9×
“In AD, for instance, rare, fully penetrant autosomal dominant mutations in 3 genes (i.e. APP, PSEN1, and PSEN2) have been shown to cause the disease, while a common, incompletely penetrant susceptibility variant (i.e., ε4 in APOE; see below) significantly increases the risk for AD.”
BackgroundInfluential
Research works printed but not linked: 1
- [92]Prusiner, S.B. 1998. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 :13363-13383.
Cited by
Items 401–500 of 678
Lipid Rafts and Development of Alzheimer’s Disease
Díaz, M. L., & Marín, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94608 · Cited by 10
Otsuki, N., Homma, T., Fujiwara, H., Kaneko, K., Hozumi, Y., Shichiri, M., Takashima, M., Ito, J., Konno, T., Kurahashi, T., et al. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.05.007 · Cited by 9
Levy, G., & Levin, B. L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.774668 · Cited by 10
“Observation 2: There Are Monogenic Forms of Aging-Related Diseases With Earlier Age of Onset Than the Sporadic Forms As exemplified by Alzheimer’s disease, Parkinson’s disease, and some types of cancer, there are rare early-onset forms of agingrelated diseases caused by fully penetrant autosomal dominant or recessive…”
BackgroundNovel Molecular Targets and Mechanisms for Neuroprotective Modulation in Neurodegenerative Disorders
Irannejad, H., Azari, A., Goodarzi, A., Jafarkhani, B., Eghbali, M., Karimi, Z., & Balef, S. S. H. (2022) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524922666220616092132 · Cited by 8
Dwyer, D. S., & Dickson, A. (2006) · International review of neurobiology · doi:10.1016/s0074-7742(06)77008-8 · Cited by 10
Alkanlı, N., & Ay, A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.82808 · Cited by 16
Can microbes combat neurodegeneration?
Blacher, E. (2021) · Science · doi:10.1126/science.abi9353 · Cited by 8
Detection of Mitochondrial Toxicity of Environmental Pollutants Using Caenorhabditis elegans
Maurer, L. L., Luz, A. L., & Meyer, J. N. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch43 · Cited by 11
Pillat, M. M., Ayupe, A. C., Juvenal, G. D. A., Meinerz, C., Glaser, T., Pellegrina, D. V. D. S., Paiva, D. D. S., Mello, C. F., Longo, B. M., Reis, E. M. R., et al. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10542-0 · Cited by 12
“In line with the view that Ab plays a role in AD pathogenesis, genes involved in autosomal dominant familial AD include amyloid precursor protein (APP) and presenilin 1 (PS1) [4].”
BackgroundPalmisani, J., Aresta, A. M., Vergaro, V., Mancini, G., Mazzola, M. C., Nisi, M., Pastore, L., Pizzillo, V., Vietro, N. D., Boncristiani, C., et al. (2025) · Molecules · doi:10.3390/molecules30194028 · Cited by 9
“In fact, although NDDs commonly have a late onset, recent evidence highlighted that NDDs can also impact early-life cognitive function, behavior, and brain structure and function [6,7].”
Jin, J., Cen, Q., Wang, H., Xin, Y., Feng, J., Cui, Y., Li, J., You, Z., Jing, F., Yu, Y., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107283 · Cited by 12
Clinical Recognition and Management of Amyotrophic Lateral Sclerosis: The Nurse's Role
Clarke, K., & Levine, T. (2011) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0b013e3182212a6c · Cited by 17
“Familial ALS, observed in only 10% of cases (Bertram & Tanzi, 2005), is inherited as an autosomal dominant disease in most cases.”
BackgroundfMRI in Neurodegenerative Diseases: From Scientific Insights to Clinical Applications
Dickerson, B. C., Agosta, F., & Filippi, M. (2016) · Neuromethods · doi:10.1007/978-1-4939-5611-1_23 · Cited by 8
Psychological Support for Health Professionals: An Interpretative Phenomenological Analysis
Volpato, E., Banfi, P. I., Valota, C., & Pagnini, F. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01816 · Cited by 9
“In particular, caring for persons affected by neuromuscular disorders and chronic respiratory disorders could be considered especially challenging and becomes more challenging as the disease progresses (Bertram and Tanzi, 2005).”
BackgroundKognitive Störungen: Koma, Delir, Demenz
Förstl, H. (2006) · Springer eBooks · doi:10.1007/3-540-30887-3_5 · Cited by 12
Behavioral Genetics of Neurodegenerative Disorders
Galimberti, D., & Scarpini, E. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_181 · Cited by 8
In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification
Ebrahimi, P., Davoudi, E., Sadeghian, R., Zadeh, A. Z., Razmi, E., Heidari, R., Morowvat, M. H., & Sadeghian, I. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03141-4 · Cited by 8
“The genetic risk factors for NDDs include certain genetic polymorphisms, family history of NDDs, and mutations in specific genes (Bertram and Tanzi 2005).”
Tiwari, P., Dwivedi, R., Kaushik, M., Tripathi, M., & Dada, R. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02363-2 · Cited by 10
Liquid–liquid phase separation in neurodegenerative diseases
Haider, R., Boyko, S., & Surewicz, W. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823967-4.00018-x · Cited by 8
Rare neurovascular genetic and imaging markers across neurodegenerative diseases
Dilliott, A. A., Berberian, S. A., Sunderland, K. M., Binns, M. A., Zimmer, J., Ozzoude, M., Scott, C. J. M., Gao, F., Lang, A. E., Breen, D. P., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13316 · Cited by 7
“43,44 However, in recent years it has become increasingly more accepted that the course and manifestation of neurodegenerative diseases are also influenced by concurrent/comorbid cerebrovascular injury.”
BackgroundBaron, M., Gómez‐Tortosa, E., Bochdanovits, Z., Gobernado, I., Rábano, A., Muñoz, D. G., Heutink, P., & Jiménez‐Escrig, A. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318215aaf4 · Cited by 8
“Of the 664 genes listed in the AlzGene database as of the end of September, 2010(1) only a few have been consistently replicated.(2) At present, a small fraction of Alzheimer cases can be explained by the genes identified thus far: the APP, PSEN1, and PSEN2.”
BackgroundNumbers of Mutations within Multicellular Bodies: Why It Matters
Frank, S. A. (2022) · Axioms · doi:10.3390/axioms12010012 · Cited by 8
Ochiai, M., Nguyen, H. T., Kurihara, N., Hirano, M., Tajima, Y., Yamada, T. K., & Iwata, H. (2021) · Environmental Science & Technology · doi:10.1021/acs.est.1c01074 · Cited by 7
Bitar, F. E., Alsudairy, N., Qadi, N., Rajeh, S. A., Alghamdi, F. O., Amari, H. A. A., Dawsari, G. A., Alsubaie, S., Sudairi, M. A., Abdulaziz, S., et al. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201130111424 · Cited by 7
Gascón, E., Calvo, A. C., Molina, N., Zaragoza, P., & Osta, R. (2024) · Biomolecules · doi:10.3390/biom14121641 · Cited by 11
Fegter, O., Santos, H., RADEMAKER, A. W., Roberts, A., & Rogalski, E. J. (2023) · Gerontology · doi:10.1159/000529984 · Cited by 6
Kordi, R., Andrews, T. J., & Hicar, M. D. (2025) · Virology · doi:10.1016/j.virol.2025.110523 · Cited by 7
Zhang, Q., Yang, K., Zhang, Z., & Zhang, R. (2021) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000508889 · Cited by 6
Pan, X., Coban‐Akdemir, Z., Gao, R., Jiang, X., Sheynkman, G., Wu, E., Huang, J. H., Sahni, N., & Yi, S. S. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad030 · Cited by 6
Applications of functionalized nanoparticles in tissue engineering
Bhutta, Z. A., Kulyar, M. F., Farooq, U., Ashar, A., Mahfooz, A., Kanwal, A., Akhtar, M. F., Asif, M., Nawaz, S., & Li, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91783-4.00006-1 · Cited by 8
Localizations of endogenous APP/APP-Proteolytic products are consistent with microtubular transport
Zitnik, G., Wang, L., Martin, G. M., & Hu, Q. (2007) · Journal of Molecular Neuroscience · doi:10.1007/bf02686118 · Cited by 7
DNA Methylation in Neuronal Development and Disease
Bruggeman, E. C., & Yao, B. (2019) · RNA technologies · doi:10.1007/978-3-030-14792-1_5 · Cited by 8
Neuronal chloride transporters in neurodegenerative diseases
Yang, L., & Justice, N. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815318-5.00023-6 · Cited by 6
Exploring Structural Flexibility and Stability of α-Synuclein by the Landau–Ginzburg–Wilson Approach
Korneev, A., Begun, A. M., Liubimov, S. D., Kachlishvili, K., Molochkov, A. V., Niemi, A. J., & Maisuradze, G. G. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c04651 · Cited by 7
Nasal chemosensory tests: biomarker between dementia with Lewy bodies and Parkinson disease dementia
Fogue, C., Lemdani, M., & Huart, C. (2020) · Rhinology Journal · doi:10.4193/rhin20.072 · Cited by 6
“In the present study, we found no impact of MMSE score on odor detection threshold results.”
MethodInfluentialLiposomal Drug Delivery for Neurological Disorders: Advances and Challenges
Javed, A., Mandal, P., Khan, I., Singh, A. P., Akhtar, J., Maheshwari, S., & Prajapati, B. G. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249319942240903134353 · Cited by 7
Ye, C., Ho, R., Moberg, K. H., & Zheng, J. Q. (2024) · eLife · doi:10.7554/elife.97908 · Cited by 8
“Recent studies have identified multiple genetic mutations and risk factors associated with dementia and neurodegeneration, but additional causes are likely involved ( Fu and Ip, 2023 ; Pihlstrøm et al., 2017 ; Bertram and Tanzi, 2005 ; Hardy and Orr, 2006 ).”
BackgroundMolecular Pathology of the Central Nervous System
Harris, B. T., & Hattab, E. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4900-3_16 · Cited by 5
Skeletal Muscle Pathogenesis in Polyglutamine Diseases
Marchioretti, C., Zuccaro, E., Pandey, U. B., Rosati, J. D., Basso, M., & Pennuto, M. (2022) · Cells · doi:10.3390/cells11132105 · Cited by 5
“Moreover, neurodegenerative diseases are characterized by the accumulation of the disease-related proteins into inclusion bodies and aggregates inside and outside the degenerating neurons [3].”
BackgroundA role of P-glycoprotein in neurology
Chernykh, I. V., Shchulkin, A. V., Yakusheva, E. N., & Popova, N. M. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20171171167-71 · Cited by 5
Toxicity and infectivity: insights from de novo prion formation
Wisniewski, B. T., Sharma, J., Legan, E. R., Paulson, E. J., Merrill, S. J., & Manogaran, A. L. (2017) · Current Genetics · doi:10.1007/s00294-017-0736-1 · Cited by 5
“However, genetic and environmental factors have also been shown to exacerbate neurodegenerative progression of these diseases (Bertram and Tanzi 2005; Campdelacreu 2014; Agrawal et al.”
Sit-to-Stand Test for Neurodegenerative Diseases Video Classification
Dentamaro, V., Impedovo, D., & Pirlo, G. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-59830-3_52 · Cited by 6
Niklasson, B., Lindquist, L., Klitz, W., Fredrikson, S., Morgell, R., Mohammadi, R., Bank, N. B., Karapetyan, Y. E., & Englund, E. M. (2022) · Microorganisms · doi:10.3390/microorganisms10030599 · Cited by 5
“Molecular epidemiological approaches have identified high-risk genes for familial neurodegenerative diseases and have also determined common genetic variants that may predict susceptibility for non-familial forms of these diseases [3,4].”
BackgroundRaeburn, C., Ormsby, A. R., Cox, D., Gerak, C. A., Makhoul, C., Moily, N. S., Ebbinghaus, S., Dickson, A., McColl, G., & Hatters, D. M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102158 · Cited by 9
“The imbalance of protein homeostasis is hypothesized to underlie the inappropriate protein misfolding and aggregation that arise in the brain of patients with common neurodegenerative diseases including Alzheimer’s, Parkinson’s, Huntington’s, and motor neuron diseases (3, 4).”
BackgroundThe Effects of Medical Conditions on Driving Performance: A Literature Review and Synthesis
Lococo, K. H., Staplin, L., Schultz, M. W., & Llc TransAnalytics (2018) · ROSA P · doi:10.21949/1525955 · Cited by 7
Sahara, N., & Lewis, J. M. (2010) · Future Neurology · doi:10.2217/fnl.10.10 · Cited by 5
“Several genes have been implicated in AD, most notably, those encoding amyloid precursor protein (APP), presenilin (PSEN)1 and 2 (reviewed in [2]).”
BackgroundThe tumor suppressor protein PTEN undergoes amyloid-like aggregation in tumor cellsPreprint
Claes, F., Maritschnegg, E., Baets, G. D., Siekierska, A., Rubio, M. S., Ramakers, M., Michiels, E., Smet, F. D., Depreeuw, J., Vergote, I. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.30.402115 · Cited by 5
“In fact, wild-type protein aggregation is the most prevalent scenario in the most common amyloidassociated neurodegenerative diseases, such as Alzheimer or Parkinson disease whereas familial forms of these diseases are much less common (Bertram and Tanzi, 2005).”
BackgroundThe role of amyloid beta 4-42 in the etiology of Alzheimer's disease
Bouter, Y. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4849 · Cited by 8
Wagaskar, P., Gaikwad, S., Suryawanshi, M. V., & Patil, A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01888-7 · Cited by 7
“1 (Bertram and Tanzi 2005).”
Genetic and epigenetic drivers of neurodegenerative disorders
Roy, K., Syed, M., Narad, P., & Sengupta, A. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.002 · Cited by 5
Protein misfolding and its dual role in neurodegeneration and cancer progression
Jamwal, R. S., Sharma, B., Minerva, Gupta, A., Misri, S., Shankaryan, R., Shah, R., & Kumar, R. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.10.001 · Cited by 5
Hao, Y., Li, C., Wang, H., & Chen, M. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1241412 · Cited by 4
Liu, X., Huang, H., Gu, Y. X., Li, J., Zhang, X., & Liu, T. (2025) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2025.3603555 · Cited by 4
“P ARKINSON’S disease (PD), the second most common neurodegenerative disorder, progressively impairs motor control, potentially leading to severe disability [1], [2].”
Nanodelivery systems for Alzheimer's disease: Prospects of natural therapeutic agents
Odeku, O. A., & Ajala, T. O. (2021) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2021.1101101 · Cited by 5
“The most common neurodegenerative diseases are amyotrophic lateral sclerosis, Huntington’s disease, frontotemporal dementia, prion diseases, and Alzheimer’s disease (AD) (Bertram and Tanzi, 2005).”
On a mechanistic impact of transmembrane tetramerization in the pathological activation of RTKs
Polyansky, A. A., & Efremov, R. G. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.04.021 · Cited by 4
“, neurodegenerative diseases in the course of which single-point mutations often lead to pathological protein aggregation [6,25,34,39].”
BackgroundSaraceno, C., Pagano, L., Laganà, V., Geviti, A., Bagnoli, S., Ingannato, A., Mazzeo, S., Longobardi, A., Fostinelli, S., Bellini, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137035 · Cited by 5
Shirian, S., Tahmasebian, N., Moghadam, B. B., Kiani, F. Z., & Amini, M. R. (2024) · The Neuroscience Journal of Shefaye Khatam · doi:10.61186/shefa.12.3.103 · Cited by 4
CPG-based circuitry for controlling musculoskeletal model of human locomotor system
Shachykov, A., Hénaff, P., Shachykov, A., Popov, A. O., & Shulyak, A. P. (2017) · IEEE Biomedical Circuits and Systems Conference (BioCAS) · doi:10.1109/biocas.2017.8325131 · Cited by 4
“It is the second most common neurodegenerative disease of adult onset [2].”
BackgroundContributing Factors of Neurodegeneration in Alzheimer’s Disease
Tailor, B. A., Pilozzi, A. R., & Huang, X. (2019) · Codon Publications eBooks · doi:10.15586/alzheimersdisease.2019.ch5 · Cited by 6
“Amyloid plaques, or the insoluble Aβ peptides, in the brain form through the cleavage of amyloid precursor protein (APP) by the b-site of APP cleaving enzyme 1 (BACE1 or β-secretase) and γ-secretase (10, 11).”
BackgroundDietary education programs for adults with neurological diseases: a scoping review protocol.
Russell, R., Black, L., & Begley, A. (2020) · JBI Evidence Synthesis · doi:10.11124/jbisrir-d-19-00394 · Cited by 3
Fibrous Polypeptide Based Bioscaffold Delivery of Minocycline Hydrochloride for Nerve Regeneration
Su, A.-J. A., Jiang, N., Luo, S., Washington, K. M., Wu, M., Huang, Y., & Su, W. (2023) · Materials Chemistry and Physics · doi:10.1016/j.matchemphys.2023.127974 · Cited by 4
A Hybrid Protection Scheme for the Gait Analysis in Early Dementia Recognition
Castro, F., Impedovo, D., & Pirlo, G. (2023) · Sensors · doi:10.3390/s24010024 · Cited by 5
“Some of the most common neurodegenerative diseases are dementia, Parkinson’s, amyotrophic lateral sclerosis, and Huntington’s [5–8].”
BackgroundBewegung zur Prävention von Demenz: Ergebnisse der evidenzbasierten Bewegungsintervention – GESTALT
Streber, A., Abu‐Omar, K., Wolff, A., & Rütten, A. (2013) · Prävention und Gesundheitsförderung · doi:10.1007/s11553-013-0424-z · Cited by 8
Coppedè, F., Bosco, P., Fuso, A., & Troen, A. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/926082 · Cited by 9
“It is worthwhile to note that GC receptor density is increased in VF compared to SF and stimulates lipolysis in the whole body [99, 100].”
BackgroundSantano, C., de Lara, M. P., & Pintor, J. J. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-956-7_10 · Cited by 6
The Genetics of Alzheimer’s Disease
Bertram, L. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_1 · Cited by 4
Self-citationAcupuncture for Parkinson's disease?
Jeon, B. S., & Lee, K. (2010) · Movement Disorders · doi:10.1002/mds.23105 · Cited by 5
Raeburn, C. B., Ormsby, A. R., Moily, N. S., Cox, D., Ebbinghaus, S., Dickson, A., McColl, G., & Hatters, D. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.19.440383 · Cited by 4
“The imbalance of protein 35 homeostasis is hypothesized to underlie the inappropriate protein misfolding and aggregation that 36 arise in the brain of patients with common neurodegenerative diseases including Alzheimer’s, 37 Parkinson’s, Huntington’s and motor neuron diseases (3,4).”
BackgroundRajalakshmi, M., Indu, S., & Vijayalakshmi, P. (2024) · Springer eBooks · doi:10.1007/978-981-99-7269-2_5 · Cited by 3
Taking flight, the use of Drosophila melanogaster for neuroscience research in Uruguay
Budelli, G., Ferreiro, M. J., & Bolatto, C. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.006 · Cited by 3
Sit-to-Stand Test for Neurodegenerative Diseases Video Classification
Convertini, V. N., Dentamaro, V., Impedovo, D., & Pirlo, G. (2021) · International Journal of Pattern Recognition and Artificial Intelligence · doi:10.1142/s021800142160003x · Cited by 3
Zhang, J., Yang, B., Luo, L., Li, L., Yang, X.-T., Zhang, J., Xie, Y., Wang, W., & Lu, S. (2021) · Parkinson s Disease · doi:10.1155/2021/6676709 · Cited by 3
“Introduction Parkinson’s disease (PD) is an age-related neurodegenerative disease that is clinically characterized by the death of dopaminergic (DA) neurons and the formation of Lewy bodies [1, 2].”
BackgroundOpuntia spp. Benefits in Chronic Diseases
Abd‐Elhakim, Y. M., & Al-Sagheer, A. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-78444-7_20 · Cited by 3
Cheah, C. H., Ling, A. P. K., Wong, Y. P., Koh, R. Y., Hussein, S., & Agrotechnology and Biosciences Division, M. N. A. (2022) · Reports of Biochemistry and Molecular Biology · doi:10.52547/rbmb.11.1.125 · Cited by 3
Thompson, J. D., Talmage, A., Jenkins, B., & Purdy, S. C. (2022) · Voices A World Forum for Music Therapy · doi:10.15845/voices.v22i2.3185 · Cited by 4
“Parkinson’s is the second leading neurodegenerative disease worldwide after Alzheimer’s disease (Bertram & Tanzi, 2005).”
BackgroundÇakır, M., & Saçmacı, H. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137683 · Cited by 4
Angiotensin detection: A comprehensive review of current methods and novel technologies
Deng, F., Wang, R., Wu, L., Yang, G., Su, R. J., & Liu, Y. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.111592 · Cited by 3
Nutritional Support in Amyotrophic Lateral Sclerosis
Stavroulakis, T., & McDermott, C. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-53171-7_6 · Cited by 4
Barmada, S. J., & Finkbeiner, S. M. (2010) · Nature Neuroscience · doi:10.1038/nn1110-1303 · Cited by 3
Cell Microencapsulation Implants into the Central Nervous System
Spuch, C., & Navarro, C. (2011) · Current Nanomedicine · doi:10.2174/1877912311101010060 · Cited by 3
Prädiktive Diagnostik neurodegenerativer Erkrankungen
Weydt, P. (2016) · Springer eBooks · doi:10.1007/978-3-662-49916-0_6 · Cited by 3
Genetic analysis of SNCA gene polymorphisms in Parkinson’s disease in an Iranian population
Rahimi, M., Akbari, M., Jamshidi, J., Tafakhori, A., Emamalizadeh, B., & Darvish, H. (2017) · Basal Ganglia · doi:10.1016/j.baga.2017.08.001 · Cited by 3
Risk Factors for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00002-1 · Cited by 4
Disease Influence on BBB Transport in Neurodegenerative Disorders
de Lange, E. C. M. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_22 · Cited by 3
The effect of somatic disorders on brain aging and dementia : Findings from population studies
Atti, A. R. (2009) · Figshare · Cited by 3
Phytochemicals Effects on Neurodegenerative Diseases
Hernández-Montiel, H. L., Solís‐S, J. C., Solís, P., Hidalgo, M. L., Chan, N. G. H., García-Noguez, L., López, J. V. R., Hernández‐Puga, G., Vergara‐Castañeda, H. A., Méndez-Villa, L., et al. (2017) · Wiley eBooks · doi:10.1002/9781119158042.ch4 · Cited by 4
Curcumin Delivery in Regenerative Medicine for Alzheimer’s Disease
Jafarisavari, Z., Hasanzadeh, E., Tayebi, L., & Asadpour, S. (2025) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-025-00482-1 · Cited by 2
SIRT6 Regulates Protein Synthesis and Folding Through Nucleolar Remodeling
Stein, D., Gallrein, C., Portillo, M., Kaluski‐Kopach, S., García-Venzor, A., Lachberg, Y., Eremenko, E., Smirnov, D., Dror, S., Einav, M., et al. (2026) · Aging Cell · doi:10.1111/acel.70384 · Cited by 8
Saini, K., & Dhiman, P. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12128-8 · Cited by 2
Nanomedical drug delivery for neurodegenerative disease
Kaur, N., Kumar, V., Mahender, T., Maji, I., Mahajan, S., Aalhate, M., Singh, P. K., & Sahu, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00016-2 · Cited by 3
Advancing the Genetics of Lewy Body Disorders with Disease‐Modifying Treatments in Mind
Levy, G., Levin, B. L., & Engelhardt, E. (2022) · Advanced Genetics · doi:10.1002/ggn2.202200011 · Cited by 1
Genome-edited rabbit, a prospective alternative model for neurological diseases
Zhang, Z., Song, Y., Lai, L., & Li, Z. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.15 · Cited by 5
Agiwale, B. T., Jadhav, A. B., Kshirsagar, S. J., Bele, M. H., Sonawane, C. R., Kakad, S. P., & Ahirrao, S. P. (2023) · Current Nanomedicine · doi:10.2174/2468187313666230228102211 · Cited by 2
Genetic and molecular basis of neurodegenerative diseases
Yogi, S., Sangeeth, A., Chimata, A. V., Padma, R., & Singh, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23826-0.00002-7 · Cited by 2
Nashwa, K. K., & Anuja, K. (2024) · International Journal of Allied Medical Sciences and Clinical Research · doi:10.61096/ijamscr.v12.iss3.2024.340-353 · Cited by 2
Modelling Population Genetic Screening in Rare Neurodegenerative Diseases
Spargo, T. P., Iacoangeli, A., Ryten, M., Forzano, F., Pearce, N. E., & Al‐Chalabi, A. (2025) · Biomedicines · doi:10.3390/biomedicines13051018 · Cited by 3
“This reasoning is therefore highly relevant to screening for rare neurodegenerative diseases, for which genetic causes are typically rare variants of variable penetrance [27].”
Role of Central Insulin-Like Growth Factor-1 Receptor Signalling in Ageing and Endocrine Regulation
Moll, L., Zemva, J., & Schubert, M. (2011) · InTech eBooks · doi:10.5772/22924 · Cited by 2
Free Cholesterol — A Double-Edge Sword in Alzheimer Disease
Fernández-Checa, J. C. (2015) · InTech eBooks · doi:10.5772/59935 · Cited by 3
Averting Dementia of the Alzheimer's Type in Women: Can Counselors Help?.
Douthit, K. Z. (2007) · Adultspan Journal · doi:10.1002/j.2161-0029.2007.tb00026.x · Cited by 2
Álvarez‐Miranda, E., Farhan, H., Luipersbeck, M., & Sinnl, M. (2016) · Annals of Operations Research · doi:10.1007/s10479-016-2188-2 · Cited by 2
“A recent study of the World Health Organization (see Duthey 2013), reports that more than 30 million people in the world are currently affected by Alzheimer’s disease, with around 5 million new cases occurring every year Bertram and Tanzi (2005), Mayeux (2003), Reitz et al. (2011).”
Background
Metadata
- Authors
- Bertram, L.
- Affiliations
- Harvard University (US)
- Corresponding author
- Bertram, L.
- ORCID
- Bertram, L.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1449-1457
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1137006
- OpenAlex
- W2110054485
- Cited by
- 680
- References
- 106
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 40 · 2023: 48 · 2022: 48 · 2021: 40 · 2020: 44 · 2019: 37 · 2018: 46 · 2017: 41 · 2016: 36 · 2015: 20 · 2014: 25 · 2013: 25 · 2012: 34
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Massachusetts General Hospital
- National Alliance for Research on Schizophrenia and Depression
- Deutsche Forschungsgemeinschaft
- National Institute on Aging
- National Institute of Mental Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- neurodegenerative diseases, genetic epidemiology, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, prion disease, common disease-common variant hypothesis, complex disease genetics, familial aggregation, genetic risk factors, single nucleotide polymorphisms, gene-environment interaction, genetic heterogeneity, pathogenesis, amyloid precursor protein, alpha-synuclein, tau protein
- MeSH terms
- Chromosome Mapping, Nerve Degeneration, Molecular Epidemiology, Neurodegenerative Diseases, Genetic Predisposition to Disease, Physical Chromosome Mapping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.